"With several ongoing contract discussions for CoreTherm® Eagle, we are positive about the interest in our treatment and the upcoming international launch"
Fourth quarter
October 1 - December 31
- Net sales amounted to SEK 3,9 million (6,4)
- Operating result amounted to SEK -6,2 million (-3,5)
- Profit after tax amounted to SEK -6,2 million (-3,5)
- Earnings per share before and after dilution amounted to SEK -2,43 (-1,82)
- Cash flow from operating activities amounted to SEK -6,5 million (-5,6)
January 1 - December 31
- Net sales amounted to SEK 13,7 million (22,1)
- Operating result amounted to SEK -22,5 million (-16,9)
- Profit after tax amounted to SEK -22,6 million (-17,0)
- Earnings per share before and after dilution amounted to SEK -6,94 (-9,94)
- Cash flow from operating activities amounted to SEK -22,6 million (-23,7)
- Cash and cash equivalents amounted to SEK 7,8 million (15,0)
Significant events during the quarter
- First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate.
- Short-term results and long-term durability after CoreTherm® treatments presented at the Emirates International Urological Conference in Dubai, UAE.
- Notice of Extraordinary General Meeting regarding a resolution on reverse share split.
- The first ten CoreTherm® Eagle machines have been manufactured.
- ProstaLund announces outcome of warrants series TO 3, with a subscription rate of 94,4%, the company received approximately SEK 3,7 million before issue costs.
- Further study published confirming the good effect of transurethral intraprostatic anaesthesia (TUIA) via our Schelin Catheter® in the treatment of benign prostatic hyperplasia.
- Nomination Committee appointed in ProstLund AB (publ) for the Annual General Meeting 2025.
- Determination of record date for reverse share split in ProstaLund AB.
Significant events after the quarter
- Older men treated with CoreTherm® for benign prostate enlargement have a lower risk of a prostate cancer diagnosis later in life compared to men treated with TURP according to a new Swedish registry study.
- New study confirms the strong efficacy of CoreTherm® in patients with large prostates.
Key figures
| (SEK MILLION) | OCT-DEC 2024 | OCT-DEC 2023 | JAN-DEC 2024 | JAN-DEC 2023 |
| Net sales | 3,9 | 6,4 | 13,7 | 22,1 |
| Gross Margin, (%) | 54,9 | 73,5 | 64,6 | 70,1 |
| Operating profit/loss, EBIT | -6,2 | -3,5 | -22,5 | -16,9 |
| Cash flow from operating activites | -6,5 | -5,6 | -23,0 | -23,7 |
| Cash and cash equivalents | 7,8 | 15,0 | 7,8 | 15,0 |
| Average number of employees | 9 | 5 | 8 | 7 |
For further information, please contact:
Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com
About ProstaLund
ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPH). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,500 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden
Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se
This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-20 07:30 CET.
